A clinical study on docetaxel plus capecitabine as front-line combination therapy for breast cancer with liver metastases
- VernacularTitle:多西紫杉醇联合卡培他滨治疗乳腺癌肝转移的临床研究
- Author:
Fu-Guo TIAN
;
Hai-Ming WU
;
Run-Qi CHEN
;
Guo-Chen ZHANG
;
Guo-Hui HAN
;
Xiao-Bo LIANG
;
Yu WANG
;
Jun GAO
;
Ling-Zhi CUI
;
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neoplasm metastasis;
Drug therapy;
Docetaxel;
Capecitabine
- From:
Cancer Research and Clinic
1999;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the efficacy and tolerability of docetaxel plus capecitabine as first-line treatment for breast cancer with liver metastases(BCLM).Methods Forty-two patients with BCLM received oral capecitabine 1900 mg/m~2/d(950 mg/m~2 twice daily)on days 1 through 14 and intravenous infu- sion of Docetaxel at 75 mg/m~2 on day 1 of each 21-day treatment cycle.Patients were evaluated for the re- sponse after two cycles.Results Among these 42 patients,the overall response rate was 54.76% with 4 CR, 19 PR, 9 SD and 6 PD.The clinical benefit rate was 64.28% and the median overall survival time was 17.5 months.The most common treatment-related adverse events were leukopenia(76.1%),neutropenia(71.4%), hand-foot syndrome(45.2%),nausea and vomiting(52.3%),which were mainly gradeⅠ～Ⅱ.Conclusion The combination of docetaxel plus capocitabine is a highly active and generally well-tolerated regimen for first-line treatment of BCLM.
